Editorial Videos

Rob Abbott, CEO, ISPOR, highlights that the United States excels in areas like cancer screening and advanced medical technology while facing challenges such as rising costs, lack of universal coverage, and health outcomes that lag behind other high-income nations.

Rob Abbott, CEO, ISPOR, highlights how emerging data strategies, advanced technology, and a renewed focus on patient needs are setting the direction for the next era of healthcare worldwide.

Rob Abbott, CEO, ISPOR, explains how health economics and outcomes research is helping healthcare systems measure the true value of treatments, improve patient outcomes, and address rising drug costs globally.

Gene Mack, CEO, Gain Therapeutics, explains how the company’s Magellan AI platform analyzes novel protein binding sites to identify and design drug candidates beyond what’s currently available in the public domain.

Gene Mack, CEO, GAIN Therapeutics, highlights early Phase Ib data showing GT-02287 may enhance neuroprotection across a wider spectrum of Parkinson’s patients regardless of genetic status.

Gene Mack, CEO, GAIN Therapeutics, outlines how early trial results for GT-02287 are shaping the company’s strategy for advancing a potential new treatment for Parkinson’s disease.

Gene Mack, CEO, GAIN Therapeutics, shares how growing clinician confidence and strong early experiences helped accelerate enrollment in the company’s Phase Ib Parkinson’s disease trial.

Gen Li discusses when the industry can expect to start seeing technological advancements implemented.

Gen Li discusses the current state of technological advancement in clinical trials.

Dr. Zeskind discusses how Immuneering’s treatments can impact a broad range of cancer types.

Gen Li discusses how competition and other factors can impact existing issues with clinical trial design.

The side effects that come with many cancer treatments can cause people to delay or avoid treatment.

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how the approval of Emrelis is accelerating investor interest, validating biomarker-driven ADCs, and shaping distinct strategic paths for pharma and biotech in the evolving precision oncology landscape.

Planning and recruitment issues can compound during this critical phase of the drug development process.

Patients should both live longer and feel better while they fight cancer.

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how the approval of Emrelis marks a pivotal moment for ADC therapies in oncology, reflecting the FDA’s growing confidence in their safety and efficacy and accelerating the shift toward precision medicine in cancer treatment.

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, discusses how Emrelis fits into the current antibody-drug conjugate landscape and what distinguishes its approach in biomarker-driven oncology.

Dr. Ben Zeskind, CEO of Immuneering, discusses the new approach his company is taking to oncology.

Corina Dutcus, SVP, oncology global clinical development lead at Eisai, discusses the potential of the E7386 and lenvatinib combination to address unmet needs in second-line treatment for endometrial carcinoma patients.

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, explains how E7386 and lenvatinib work together to target advanced endometrial carcinoma through dual mechanisms of action and WNT pathway modulation.

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how long-term LEAP-002 data provides critical reassurance around Lenvima’s durability and safety in treating unresectable hepatocellular carcinoma.

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how consistent survival data from the LEAP-002 study reaffirms lenvatinib’s value in first-line treatment of unresectable hepatocellular carcinoma.

Marcel Botha discusses whether AI can truly be used to replace laid off human workers at FDA.

Marcel Botha discusses ways the agency can ensure it gets the most accurate results possible from AI.

Marcel Botha discusses what the technology is most effective at in the FDA approval process.

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, outlines how the company is working to ease care transitions, support community oncologists, and reduce overwhelm in cancer treatment delivery.

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, shares how the company is supporting cancer care teams through timely education, community-based trials, and tools to manage complex treatment transitions.

Between tariffs, funding cuts, and changes at HHS, pharma is facing new challenges.